Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report.

GE Portuguese journal of gastroenterology

Russo P, Costa M, Silva M, de Sousa A, Carvalho D, Saiote J, Mendes M.
PMID: 28848800
GE Port J Gastroenterol. 2017 May;24(3):147-150. doi: 10.1159/000452694. Epub 2017 Jan 19.

The continuous delivery of a levodopa/carbidopa gel suspension (Duodopa®) into the small bowel through a jejunal tube inserted via percutaneous endoscopic gastrostomy represents a new treatment method in advanced Parkinson disease. Some severe device-related complications have been described in...

Cite
Russo P, Costa M, Silva M, et al. Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report. GE Port J Gastroenterol. 2017;24(3):147-150doi: 10.1159/000452694.
Russo, P., Costa, M., Silva, M., de Sousa, A., Carvalho, D., Saiote, J., & Mendes, M. (2017). Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report. GE Portuguese journal of gastroenterology, 24(3), 147-150. https://doi.org/10.1159/000452694
Russo, Pedro, et al. "Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report." GE Portuguese journal of gastroenterology vol. 24,3 (2017): 147-150. doi: https://doi.org/10.1159/000452694
Russo P, Costa M, Silva M, de Sousa A, Carvalho D, Saiote J, Mendes M. Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report. GE Port J Gastroenterol. 2017 May;24(3):147-150. doi: 10.1159/000452694. Epub 2017 Jan 19. PMID: 28848800; PMCID: PMC5553370.
Copy Download .nbib Format: NLM
The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients.

Pharmacy practice

Faddoul L, Chahine B, Haydar S, Abourida S, Hallit S, Raad EB.
PMID: 30637025
Pharm Pract (Granada). 2018 Oct-Dec;16(4):1220. doi: 10.18549/PharmPract.2018.04.1220. Epub 2018 Dec 19.

OBJECTIVE: The objective of this study is to compute the potential benefit of Pramipexole ER on total levodopa equivalent dose (LED) and Unified Parkinson Disease Rating Score (UPDRS-III) compared to mono- or combined therapy of pramipexole IR and/or carbidopa/levodopa.METHODS:...

Cite
Faddoul L, Chahine B, Haydar S, et al. The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients. Pharm Pract (Granada). 2018;16(4):1220doi: 10.18549/PharmPract.2018.04.1220.
Faddoul, L., Chahine, B., Haydar, S., Abourida, S., Hallit, S., & Raad, E. B. (2018). The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients. Pharmacy practice, 16(4), 1220. https://doi.org/10.18549/PharmPract.2018.04.1220
Faddoul, Lama, et al. "The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients." Pharmacy practice vol. 16,4 (2018): 1220. doi: https://doi.org/10.18549/PharmPract.2018.04.1220
Faddoul L, Chahine B, Haydar S, Abourida S, Hallit S, Raad EB. The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients. Pharm Pract (Granada). 2018 Oct-Dec;16(4):1220. doi: 10.18549/PharmPract.2018.04.1220. Epub 2018 Dec 19. PMID: 30637025; PMCID: PMC6322989.
Copy Download .nbib Format: NLM
Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence.

Frontiers in neurology

Storelli E, Cassina N, Rasini E, Marino F, Cosentino M.
PMID: 30733703
Front Neurol. 2019 Jan 24;10:13. doi: 10.3389/fneur.2019.00013. eCollection 2019.

Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss of dopaminergic neurons, appearance of Lewy bodies and presence of neuroinflammation. No treatments currently exist to prevent PD or delay its progression, and dopaminergic substitution treatments just relieve...

Cite
Storelli E, Cassina N, Rasini E, et al. Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence. Front Neurol. 2019;10:13doi: 10.3389/fneur.2019.00013.
Storelli, E., Cassina, N., Rasini, E., Marino, F., & Cosentino, M. (2019). Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence. Frontiers in neurology, 1013. https://doi.org/10.3389/fneur.2019.00013
Storelli, Elisa, et al. "Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence." Frontiers in neurology vol. 10 (2019): 13. doi: https://doi.org/10.3389/fneur.2019.00013
Storelli E, Cassina N, Rasini E, Marino F, Cosentino M. Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence. Front Neurol. 2019 Jan 24;10:13. doi: 10.3389/fneur.2019.00013. eCollection 2019. PMID: 30733703; PMCID: PMC6353825.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries